title: Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis.
abstract: OBJECTIVE
  To demonstrate the pharmacodynamic comparability between oral 40 mg pantoprazole delayed-release granules and tablets.
  
  
  METHODS
  This was a multicentre, randomized, open-label, 2-period, 2-sequence, 9-week crossover study in patients aged 18-65 years with gastro-oesophageal reflux disease and documented erosive oesophagitis. The primary endpoint was a comparison of the inhibition of pentagastrin-stimulated maximum acid output (MAO) at steady state after once daily dosing for 1 week and 23 h after the last dose of pantoprazole granules and tablets. Basal acid output was measured prior to MAO. Standard safety evaluations were performed. The one-sided t-test was used to test the null hypothesis that granules - 1.2 x tablet >/= 0 against the alternative hypothesis that this difference was <0 for both MAO and basal acid output values.
  
  
  RESULTS
  Sixty patients completed the study. The mean MAO values were 7.11 +/- 4.98 and 7.29 +/- 4.77 mmol/h, while the mean basal acid output values were 0.74 +/- 0.91 and 0.58 +/- 0.63 mmol/h for the granules and tablets, respectively. The two formulations were shown statistically to be pharmacodynamically equivalent in suppressing MAO (P = 0.006), safe and well tolerated.
  
  
  CONCLUSIONS
  Patients with gastro-oesophageal reflux disease who are unable to swallow the tablet may safely be prescribed the pantoprazole sodium granules.
authors.affiliation: Clinical Applications Lab., Inc., San Diego, CA, USA.
authors.forename: D
authors.initials: D
authors.lastname: Hogan
authors.forename: V
authors.initials: V
authors.lastname: Pratha
authors.forename: D
authors.initials: D
authors.lastname: Riff
authors.forename: S
authors.initials: S
authors.lastname: Ducker
authors.forename: H
authors.initials: H
authors.lastname: Schwartz
authors.forename: E
authors.initials: E
authors.lastname: Soffer
authors.forename: W
authors.initials: W
authors.lastname: Wang
authors.forename: N
authors.initials: N
authors.lastname: Rath
authors.forename: G M
authors.initials: GM
authors.lastname: Comer
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D018592:Cross-Over Studies; D004941:Esophagitis / Q000188:drug therapy*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D000077402:Pantoprazole